The rise of antimicrobial use in the twentieth century has significantly reduced morbidity due to infection, however it has also brought with it the rise of increasing resistance. Some patients are on prolonged, if not “life-long” course of antibiotics. The reasons for this are varied, and include non-infectious indications. We aimed to study the characteristics of this potential source of antibiotic resistance, by exploring the antibiotic dispensing practices and describing the population of patients on long-term antibiotic therapy. A retrospective cross-sectional study of antibiotic dispensing records was performed at a large university hospital-based healthcare network in Melbourne, Australia. Outpatient prescriptions were extracted from the hospital pharmacy database over a 6 month period in 2014. Medical records of these patients were reviewed to determine the indication for prescription, including microbiology, the intended duration, and the prescribing unit. A descriptive analysis was performed on this data. 66,127 dispensing episodes were reviewed. 202 patients were found to have been prescribed 1 or more antibiotics with an intended duration of 1 year or longer. 69/202 (34%) of these patients were prescribed prolonged antibiotics for primary prophylaxis in the setting of immunosuppression. 43/202 (21%) patients were prescribed long-term suppressive antibiotics for infections of thought incurable (e.g. vascular graft infections), and 34/43 (79%) were prescribed by Infectious Diseases doctors. 66/202 (33%) patients with cystic fibrosis were prescribed prolonged courses of macrolides or fluoroquinolones, by respiratory physicians. There was great heterogeneity noted in indications for prolonged antibiotic courses, as well as antibiotic agents utilised. Our study found that that continuous antibiotic therapy represented only a small proportion of overall antibiotic prescribing at our health network. Prolonged courses of antibiotics were used mainly to suppress infections thought incurable, but also as primary and secondary prophylaxis and as anti-inflammatory agents. More research is needed to understand the impact of long-term antibiotic consumption on both patients and microbial ecology.
Background: Little is known about the impacts at an individual level of long-term antibiotic consumption. We explored health outcomes of long-term antibiotic therapy prescribed to a cohort of patients to suppress infections deemed incurable. Methods: We conducted a 5-year longitudinal study of patients on long-term antibiotics at Monash Health, a metropolitan tertiary-level hospital network in Australia. Adults prescribed antibiotics for >12 months to suppress chronic infection or prevent recurrent infection were included. A retrospective review of medical records and a descriptive analysis was conducted. Results: Twenty-seven patients were followed up during the study period, from 29 patients originally identified in Monash Health in 2014. Seven of the 27 patients (26%) died from causes unrelated to the suppressed infection, six (22%) ceased long-term antibiotic therapy and two (7%) required treatment modification. Fifteen (56%) were colonised with multiresistant microorganisms, including vancomycin resistant Enterococci, methicillin resistant Staphylococcus aureus, and carbapenem resistant Enterobacteriaciae. Conclusions: This work highlights the potential pitfalls of long-term antibiotic therapy, and the frailty of this cohort, who are often ineligible for definitive curative therapy.
We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.
22 January 2024 in Infection Control & Hospital Epidemiology
Background: Lifelong antibiotic therapy can be used as a strategy to manage chronic infections deemed incurable. While this may be beneficial in suppressing infections, its long-term consequences remain underexplored. Methods: Conducted at a tertiary healthcare network in Melbourne, Australia, this 10-year longitudinal observational study, starting in 2015, followed up an initial cohort of 29 patients prescribed suppressive long-term antibiotics. Data extracted from medical records included patient demographics, antibiotic use, adverse events, mortality, and Charlson Comorbidity Index scores. Outcomes were assessed using descriptive statistics. Results: Of the original cohort of 29 patients in 2015, 19 were still alive at the five-year follow-up, with 14 of those continuing antibiotic therapy. At the 10-year follow-up, an additional three patients had died (total 11/29; 38%), and one had ceased antibiotics (total 6/29; 21%). Notably, none of the patients who had previously ceased antibiotics resumed therapy. Four patients were lost to follow-up, and only two patients were seen by infectious disease specialists for their long-term antibiotic therapy. Ultimately, of the original 29 patients initially recruited, only seven patients were confirmed to remain on antimicrobials by the 10-year follow-up. Conclusions: This 10-year prospective study highlights the complexities of lifelong antibiotic therapy. While some patients may benefit from prolonged antibiotic therapy with prevention of relapsed infection, the high burden of comorbidities, therapy adjustments, and hospitalizations remains a challenge. Long-term care strategies and individualized treatment approaches are essential. Further research is needed to optimize outcomes and refine criteria for lifelong antibiotic use and its management.